Taurochenodeoxycholic acid (12-Deoxycholyltaurine)
(Synonyms: 牛磺鹅去氧胆酸; 12-Deoxycholyltaurine) 目录号 : GC33825
Taurochenodeoxycholic acid (12-Deoxycholyltaurine)是一种牛磺酸结合胆汁酸。
Cas No.:516-35-8
Sample solution is provided at 25 µL, 10mM.
Taurochenodeoxycholic acid (12-Deoxycholyltaurine) is a taurine-conjugated bile acid [1]. Taurochenodeoxycholic acid activates receptors such as FXR (farnesoid X receptor) and TGR5, regulating liver, intestinal and systemic metabolism [2-3]. Taurochenodeoxycholic acid is mainly studied in glucose metabolism, lipid metabolism, and inflammatory response [4].
In NR8383 cells, Taurochenodeoxycholic acid (1-100μM; 48h) treatment enhanced the apoptosis rate of cells [5]. In fibroblast-like synoviocytes, Taurochenodeoxycholic acid (50-400μg/mL; 48h) induces apoptosis of cells [6]. In SGC-7901 cells, aurochenodeoxycholic acid (0-100μg/mL; 12-48h) inhibits the proliferation and invasion of gastric cancer and induces its apoptosis [7].
In experimental autoimmune encephalomyelitis (EAE) mice model, Taurochenodeoxycholic acid (25mg/kg, 50mg/kg; po; 23d) administration could improve the nerve damage of EAE mice [8]. In Staphylococcus aureus-infected mice, Taurochenodeoxycholic acid (0.1μg/g; ip; 1h) reduced secretion levels of inflammatory mediators and lung injury in Staphylococcus aureus-infected mice via TLR2 [9].
References:
[1]. Uchida A, Yamada T, Hayakawa T, et al. Taurochenodeoxycholic acid ameliorates and ursodeoxycholic acid exacerbates small intestinal inflammation[J]. American Journal of Physiology-Gastrointestinal and Liver Physiology, 1997, 272(5): G1249-G1257.
[2]. Song G, Weng F, Zou B, et al. Potential therapeutic action of tauroursodeoxycholic acid against cholestatic liver injury via hepatic Fxr/Nrf2 and CHOP-DR5-caspase-8 pathway[J]. Clinical Science, 2023, 137(7): 561-577.
[3]. Qi Y, Shi L, Duan G, et al. Taurochenodeoxycholic acid increases cAMP content via specially interacting with bile acid receptor TGR5[J]. Molecules, 2021, 26(23): 7066.
[4]. Bao L, Hao D, Wang X, et al. Transcriptome investigation of anti‐inflammation and immuno‐regulation mechanism of taurochenodeoxycholic acid[J]. BMC Pharmacology and Toxicology, 2021, 22(1): 23.
[5]. Wang X, Zhang Z, He X, et al. Taurochenodeoxycholic acid induces NR8383 cells apoptosis via PKC/JNK-dependent pathway[J]. European Journal of Pharmacology, 2016, 786: 109-115.
[6]. Li L, Liu C, Liu M, et al. Taurochenodeoxycholic acid induces apoptosis of fibroblast-like synoviocytes[J]. European journal of pharmacology, 2013, 706(1-3): 36-40.
[7]. Zhang D, Zhu Y, Su Y, et al. Taurochenodeoxycholic acid inhibits the proliferation and invasion of gastric cancer and induces its apoptosis[J]. Journal of Food Biochemistry, 2022, 46(3): e13866.
[8]. Xu N, Bai Y, Han X, et al. Taurochenodeoxycholic acid reduces astrocytic neuroinflammation and alleviates experimental autoimmune encephalomyelitis in mice[J]. Immunobiology, 2023, 228(3): 152388.
[9]. Gong Z, Mao W, Ren P, et al. Taurochenodeoxycholic acid ameliorates the Staphylococcus aureus infection-induced acute lung injury through toll-like receptor 2 in mice[J]. International Immunopharmacology, 2024, 142: 113228.
Taurochenodeoxycholic acid (12-Deoxycholyltaurine)是一种牛磺酸结合胆汁酸 [1]。Taurochenodeoxycholic acid激活FXR（法尼醇X受体）和TGR5等受体，调节肝脏、肠道和全身代谢 [2-3]。Taurochenodeoxycholic acid主要在糖代谢、脂质代谢和炎症反应方面进行研究 [4]。
在NR8383细胞中，Taurochenodeoxycholic acid（1-100μM；48h）处理可增加细胞凋亡率 [5]。在成纤维细胞样滑膜细胞中，Taurochenodeoxycholic acid（50-400μg/mL；48h）可诱导细胞凋亡 [6]。在SGC-7901细胞中，Taurochenodeoxycholic acid（0-100μg/mL；12-48h）可抑制胃癌的增殖和侵袭，并诱导其凋亡 [7]。
在实验性自身免疫性脑脊髓炎（EAE）小鼠模型中，Taurochenodeoxycholic acid（25mg/kg、50mg/kg；po；23d）给药可改善EAE小鼠的神经损伤 [8]。在金黄色葡萄球菌感染小鼠中，Taurochenodeoxycholic acid（0.1μg/g；ip；1h）通过TLR2降低金黄色葡萄球菌感染小鼠炎症介质的分泌水平和肺损伤 [9]。
| Cell experiment [1]: | |
Cell lines | NR8383 cells |
Preparation Method | FITC Annexin V and Prodium Iodide (PI) binding was used to identify the existence of apoptosis. Cells were treated with different concentrations of Taurochenodeoxycholic acid (100μM, 10μM, 1μM) for 48h, while control NR8383 cells were incubated in DMEM alone. |
Reaction Conditions | 1-100μM; 48h |
Applications | Taurochenodeoxycholic acid treatment enhanced the apoptosis rate of NR8383 cells. |
| Animal experiment [2]: | |
Animal models | Experimental autoimmune encephalomyelitis (EAE) mice model |
Preparation Method | C57BL/6 mice (female, 5-week-old) for 12h daily light at 25 ± 1℃ on a free diet and water, and they were divided into the Control, EAE, EAE + Taurochenodeoxycholic acid (TCDCA) 50mg/kg, EAE + TCDCA 25mg/kg, and EAE + Methylpredinisolone groups. For EAE induction, each mouse except that in the Control group was subcutaneously injected with the emulsion of Freund’s adjuvant which contained heat-killed Mycobacterium tuberculosis H37RA (500μg/mouse) and MOG35–55 (300μg/mouse). Afterward, the mice were intraperitoneally injected with pertussis toxin (PTX, 250ng/mouse) immediately and again after 48h. The Control group was only injected with the emulsion of Freund’s adjuvant without MOG35–55. |
Dosage form | 25mg/kg, 50mg/kg; po; 23d |
Applications | Taurochenodeoxycholic acid administration could improve the nerve damage of EAE mice. |
References: | |
| Cas No. | 516-35-8 | SDF | |
| 别名 | 牛磺鹅去氧胆酸; 12-Deoxycholyltaurine | ||
| Canonical SMILES | C[C@@]1([C@@]2([H])[C@H](C)CCC(NCCS(=O)(O)=O)=O)[C@](CC2)([H])[C@@]([C@@H](C[C@]3([H])C[C@H](O)CC4)O)([H])[C@]([C@]34C)([H])CC1 | ||
| 分子式 | C26H45NO6S | 分子量 | 499.7 |
| 溶解度 | DMSO : ≥ 25 mg/mL (50.03 mM) | 储存条件 | Store at RT |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0012 mL | 10.006 mL | 20.012 mL |
| 5 mM | 0.4002 mL | 2.0012 mL | 4.0024 mL |
| 10 mM | 0.2001 mL | 1.0006 mL | 2.0012 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet